Food and Drug Administration (FDA) Administrative Contacts DIS Liaisons for Visiting Scientist (FTE) cases

Size: px
Start display at page:

Download "Food and Drug Administration (FDA) Administrative Contacts DIS Liaisons for Visiting Scientist (FTE) cases"

Transcription

1 Office of Research Services DIVISION OF INTERNATIONAL SERVICES DATA SHEET Food and Drug Administration (FDA) Administrative Contacts DIS Liaisons for Visiting Scientist (FTE) cases Tania Tse Director, Office of Human Resources 7700 Wisconsin Ave. Rm Bethesda, MD Phone: Administrative Contacts for FDA Centers: OFFICE OF THE COMMISSIONER (OC)/ OFFICE OF POLICY, PLANNING, LEGISLATION, AND ANALYSIS (OPPLA): FDA Center: FDA/OC/OPPLA Division: Management and Operations Contact: Linda Fobbs Human Capital Officer Address: New Hampshire Ave., WO 1 Rm 2308A Silver Spring, Md Phone: Fax: linda.fobbs@fda.hhs.gov FDA Center: FDA/OC/OPPLA Division: Management and Operations Contact: *Pamela Hatcher (EOD: 12/15/2014) Management Officer Address: New Hampshire Ave., WO 1 Silver Spring, Md Phone: Fax: Pamela.hatcher@fda.hhs.gov HUMAN RESOURCE CONTACT FOR FDA/NCTR: Glenda Miller

2 CENTER FOR DRUG EVALUATION AND RESEARCH (CDER): Super Office: Office of Pharmaceutical Science (OPS) Component Offices: Office of Pharmaceutical Science (IO) Office of Testing and Research (OTR) Office of Biotechnology Products (OBP) Contact: Kimberly Griffin Lead Administrative Officer Building 51, Room 4120, Silver Spring, MD Phone: Fax: Contact: Address: Phone: Fax: Tarnzetta Hampton Office of Testing and Research (OTR) Management and Program Analyst New Hampshire Avenue Building 51, Room 4122, Silver Spring, MD Office of New Drug Quality Assessment (ONDQA) Contact: Noreen Gomez Lead Management and Program Analyst Building 51, Room 4112, Silver Spring, MD Phone: Fax: Super Office: Office of Translational Sciences (OTS) Component Offices: Office of Clinical Pharmacology (OCP) Office of Biostatistics (OB) Office of Computational Science (OCS) Contact: Michelle DeNamur Lead Management & Program Analyst Building 21, Room 4551 Phone: Fax:

3 Office: Office of Generic Drugs (OGD) Contact: Trevelin Prysock Management & Program Analyst Address: New Hampshire Ave Building 75, Room 1644 Phone: Fax: Super Office: Office of New Drugs (OND) Contact: Eldridge Coles Senior Supervisory Management Officer Phone: Fax: Center: FDA/CDER Super Office: Office of Surveillance and Epidemiology Component Offices: Office of Medication Error Prevention and Risk Management Office of Pharmacovigilance & Epidemiology Contact: Kristal Davis Lead Management & Program Analyst Address: New Hampshire Avenue Building 22, Room 4328 Phone: Fax: HUMAN RESOURCE CONTACT FOR FDA/CDER: Bridget Meggett CENTER FOR VETERINARY MEDICINE (CVM): Center: FDA/CVM Division: Office of Management Contact: Susan Banks (Lead Liaison) Address: MPN5 Rockville, MD Phone: Fax: HUMAN RESOURCE CONTACT FOR FDA/CVM: Keya Duke

4 CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER): Center: FDA/CBER Division: Programs Operations Branch Contact: Dawn White (Lead Liaison) Supervisory Program Analyst (Human Capital) Address: New Hampshire Ave, RM6308 Silver Spring, MD Phone: Fax: Center: FDA/CBER Division: Program Operations Branch Contact: Mariela Mercedes Address: New Hampshire Ave, RM6308 Silver Spring, MD Phone: Fax: HUMAN RESOURCE CONTACT FOR FDA/CBER: Vernon Davis CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH): Center: Office: Division: Contact: Address: Phone: Fax: FDA/CDRH Office of Device Evaluation (ODE) Program Management Staff Lesa Dowtin Supv Public Health Advisor New Hampshire Avenue Bldg. 66, Rm Silver Spring, MD Center: FDA/CDRH Office: Office of Science and Engineering Laboratories (OSEL) Division: Division of Administrative & Support Staff (DALS) Contact: Sharon Bane Program Analyst White Oak Building 62, Room 4126A Phone: Fax:

5 Center: FDA/CDRH Office: Office of Surveillance and Biometrics (OSB) Contact: Valarie Rojas / Arlene Traore/Maureen Lampe/Carolyn Bell / Program Support Specialist WO Bldg 66 Rooms 2322 / 2320 Phone: / 5763 Fax: / valarie.rojas@fda.hhs.gov / Arlene.traore@fda.hhs.gov Center: FDA/CDRH Office: Office of In Vitro Diagnostics and Radiological Health Contact: Waleska Rodriquez Gonzalez WO Bldg 66/Room 5661 Phone: Fax: Waleska.RodriquezGonzalez@fda.hhs.gov HUMAN RESOURCE CONTACT FOR FDA/CDRH: Glenda Miller CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (CFSAN): Center: FDA/CFSAN Office: Office of the Center Director/ Office of Management Systems Division: OCD/ORS/OAO Contact: Rachel N. West Address: HFS-690 Wiley Building Room 4C-061, HFS Paint Branch Parkway College Park, MD Room 4C-061 Phone: Fax: Rachel.West@fda.hhs.gov Center: FDA/CFSAN Office: Office of Management/Division of Workforce Management Division: Office of Applied Research & Safety Assessment Contact: Raquel Glenn Program Analyst Address: HFS-690, Wiley Building 5100 Paint Branch Parkway College Park, MD Room 4C-063 Phone: Fax: Raquel.Glenn@fda.hhs.gov

6 HUMAN RESOURCE CONTACT FOR FDA/CFSAN: Sabrina Lewis NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR): FDA Center: FDA/NCTR Division: Office of Executive Programs & Services Contact: Moses Robinson Associate Director, Executive Programs and Services Staff Address: 3900 NCTR Road, HFT-300 Jefferson, AR Phone: Fax: FDA Center: FDA/NCTR Division: Office of Executive Programs & Services Contact: Cynthia Davis Address: 3900 NCTR Road, HFT-300 Jefferson, AR Phone: Fax: HUMAN RESOURCE CONTACT FOR FDA/NCTR: Glenda Miller

Food and Drug Administration COMMISSIONER S. Fellowship Program. Protecting Public Health Through Science and Regulation

Food and Drug Administration COMMISSIONER S. Fellowship Program. Protecting Public Health Through Science and Regulation DEPARTMENT OF HEALTH & HUMAN SERVICES USA Food and Drug Administration COMMISSIONER S Fellowship Program Protecting Public Health Through Science and Regulation FDA MISSION The FDA is responsible for protecting

More information

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS SMG 1117.2112 FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF INFORMATION MANAGEMENT AND TECHNOLOGY OFFICE OF INFORMATION MANAGEMENT

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special

More information

Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. February 19, 2014

Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. February 19, 2014 Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair February 19, 2014 FDA Mission FDA is responsible for: Protecting the public health by assuring that foods are safe,

More information

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices;

More information

Guidance for Industry

Guidance for Industry Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,

More information

Guidance for Clinical Investigators, Sponsors, and IRBs

Guidance for Clinical Investigators, Sponsors, and IRBs Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center

More information

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human

More information

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and

More information

FY '10 Staff College Internal Training Summary Report. From 10/01/2009 to 03/31/2010. As of:

FY '10 Staff College Internal Training Summary Report. From 10/01/2009 to 03/31/2010. As of: FY '10 Staff College Internal Training Summary Report From 10/01/2009 to 03/31/2010 As of: 04/09/2010 FY 2010 1 st and 2 nd Quarter MDUFA-Related Training FDA continues to invest in internal and external

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Medical Device Reporting Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Session Overview Purpose: To provide information about the

More information

Food and Drug Administration

Food and Drug Administration Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS

More information

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Electronic Copies of Electronic Records

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Electronic Copies of Electronic Records Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Electronic Copies of Electronic Records Draft Guidance This guidance document is being distributed for comment purposes only.

More information

Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps

Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Time Stamps Draft Guidance This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER

Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation

More information

Use of Electronic Health Record Data in Clinical Investigations

Use of Electronic Health Record Data in Clinical Investigations Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed

More information

An Introduction to Genomics and SAS Scientific Discovery Solutions

An Introduction to Genomics and SAS Scientific Discovery Solutions An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!

More information

Chapter 8 EMERGENCY PROCEDURES

Chapter 8 EMERGENCY PROCEDURES This chapter contains the following sections. Chapter 8 EMERGENCY PROCEDURES Section Topic Page 8-1 PURPOSE... 8-1 8-2 INTRODUCTION... 8-1 8-3 RESPONSIBILITY... 8-2 8-4 NOTIFICATION OF EMERGENCIES... 8-3

More information

Public Health. Biostatistician. Environmental Scientist. Health Educator. Health Policy and Management. Epidemiologist. Academic Requirements

Public Health. Biostatistician. Environmental Scientist. Health Educator. Health Policy and Management. Epidemiologist. Academic Requirements Public Health Biostatistician Environmental Scientist Health Educator Health Policy and Management Epidemiologist Workers in public health fields focus on the community, national, and global health of

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics DRAFT GUIDANCE This guidance

More information

A FDA Perspective on Nanomedicine Current Initiatives in the US

A FDA Perspective on Nanomedicine Current Initiatives in the US A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for

More information

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

Consumer Representative Members Public Meeting. CDR Dornette Spell-LeSane, MHA, MSN, NP-C. Rockville, MD 30 April 2010. Deputy Director, ACOMS

Consumer Representative Members Public Meeting. CDR Dornette Spell-LeSane, MHA, MSN, NP-C. Rockville, MD 30 April 2010. Deputy Director, ACOMS Consumer Representative Members Public Meeting CDR Dornette Spell-LeSane, MHA, MSN, NP-C Deputy Director, ACOMS Rockville, MD 30 April 2010 E- mail address is dornette.spelllesane @ fda.hhs.gov Major points

More information

Determination of Regulatory Review Period for Purposes of Patent Extension;

Determination of Regulatory Review Period for Purposes of Patent Extension; This document is scheduled to be published in the Federal Register on 12/15/2015 and available online at http://federalregister.gov/a/2015-31400, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices

Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. March 3, 2015

Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair. March 3, 2015 Office of Acquisitions & Grants Services (OAGS) FDA Small Business Outreach Vendor Fair March 3, 2015 Agenda Who we are What we buy Goals and statistics Partnering with OAGS 2 FDA Mission FDA is responsible

More information

Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)

Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document

More information

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF HUMAN RESOURCES

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF HUMAN RESOURCES SMG 1117.37 FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF HUMAN RESOURCES DIVISION OF HUMAN RESOURCE SERVICES FOR THE OMPT

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,

More information

Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA

Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) DRAFT GUIDANCE

More information

Guidance for Industry Consumer-Directed Broadcast Advertisements

Guidance for Industry Consumer-Directed Broadcast Advertisements Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food

More information

Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Arthritis Advisory Committee Meeting October 23, 2015

Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Arthritis Advisory Committee Meeting October 23, 2015 Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the October 23, 2015 Location: FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503), 10993

More information

Best Practices for Communication Between IND Sponsors and FDA During Drug Development Guidance for Industry and Review Staff

Best Practices for Communication Between IND Sponsors and FDA During Drug Development Guidance for Industry and Review Staff Best Practices for Communication Between IND Sponsors and FDA During Drug Development Guidance for Industry and Review Staff Good Review Practice DRAFT GUIDANCE This guidance document is being distributed

More information

Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. www.preferredregulatoryconsulting.com 1

Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. www.preferredregulatoryconsulting.com 1 Plamena Entcheva-Dimitrov, PhD, RAC On-line Course 1 The Preferred Regulatory Consulting content in this presentation is copyright protected under United States law and applicable international copyright

More information

Quality Management Plan for the Chemistry Manufacturing and Controls Review Process

Quality Management Plan for the Chemistry Manufacturing and Controls Review Process Quality Management Plan for the Chemistry Manufacturing and Controls Review Process Final, September 13, 2007 Neptune and Company, Inc. Submitted by: Dean Neptune, Kevin Hull, Daniel Michael, Kelly Bennett,

More information

How To Exempt From Reporting And Recordkeeping Requirements For Tv And Computer Monitors With Cathode Ray Tubes

How To Exempt From Reporting And Recordkeeping Requirements For Tv And Computer Monitors With Cathode Ray Tubes Guidance for Industry and FDA Staff Exemption from Certain Reporting and Recordkeeping Requirements for Television Receivers and Computer Monitors with Cathode Ray Tubes Document issued on October 20,

More information

Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry

Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry Use of Electronic Informed Consent in Clinical Investigations Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO This document is scheduled to be published in the Federal Register on 05/29/2014 and available online at http://federalregister.gov/a/2014-12349, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Guidance for Industry

Guidance for Industry Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance

More information

Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors

Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors This document is scheduled to be published in the Federal Register on 01/08/2016 and available online at http://federalregister.gov/a/2016-00149, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Guidance for Industry and Food and Drug Administration Staff

Guidance for Industry and Food and Drug Administration Staff Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document

More information

FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research

FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research FDA White Oak Campus, Building 31, the Great Room (Rm. 1503) White Oak Conference Center, Silver Spring, Maryland DRAFT OPEN SESSION

More information

SUBJECT: Combination Product Review, Intercenter Consult Process Study

SUBJECT: Combination Product Review, Intercenter Consult Process Study DATE: October 14, 2015 TO: Associate Commissioner for Planning FROM: Deputy Commissioner for Medical Products and Tobacco SUBJECT: Combination Product Review, Intercenter Consult Process Study Thank you

More information

Good Review Practice. October 2009 Labeling

Good Review Practice. October 2009 Labeling Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good

More information

The goals of this program in the Department of Exercise Science are to:

The goals of this program in the Department of Exercise Science are to: Department of Exercise Science Master of Science in Exercise Science Clinical Exercise Physiology 2014-2015 Program Director Dr. Larry Hamm Department of Exercise Science 950 New Hampshire Avenue, NW Washington,

More information

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was

More information

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

FOOD AND DRUG ADMINISTRATION

FOOD AND DRUG ADMINISTRATION DESIGNATED FEDERAL OFFICER (Non-Voting) MEETING ROSTER Kalyani Bhatt, M.S. Division of Advisory Committee and Consultant Management Office of Executive Programs ADVISORY COMMITTEE FOR REPRODUCTIVE HEALTH

More information

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office

More information

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration

More information

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50. Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human

More information

Safety Assessment for IND Safety Reporting Guidance for Industry

Safety Assessment for IND Safety Reporting Guidance for Industry Safety Assessment for IND Safety Reporting Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

An Invitation to Collaborate

An Invitation to Collaborate Organization Name: _ An Invitation to Collaborate The invites you to collaborate with them on a campaign called Take Time To Care (TTTC). Launched in 1998, the TTTC campaign disseminates free FDA health

More information

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

Guidance for Industry DRAFT GUIDANCE

Guidance for Industry DRAFT GUIDANCE DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE

More information

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)-524-3270

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)-524-3270 SIEM EN S Abbreviated 510(k) Premnarket Notification IMMULITE 2000 PSA Calibration Verification Material 6. 510(k) Summary as Required by 21 CFR 807.92 K( - is-1 3 (v A. 5 10(k) Number: B. Purpose for

More information

Review of CBER's Current and Planned Post-marketing Safety Practices

Review of CBER's Current and Planned Post-marketing Safety Practices Review of CBER's Current and Planned Post-marketing Safety Practices Robert Ball MD, MPH, ScM Director, Office of Biostatistics and Epidemiology (OBE), Center for Biologics Evaluation and Research (CBER),

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Guidance for Clinical Investigators, Industry, and FDA Staff Financial Disclosure by Clinical Investigators

Guidance for Clinical Investigators, Industry, and FDA Staff Financial Disclosure by Clinical Investigators Guidance for Clinical Investigators, Industry, and FDA Staff Financial Disclosure by Clinical Investigators U.S. Department of Health and Human Services Food and Drug Administration Office of Good Clinical

More information

Guidance for Industry Classifying Resubmissions in Response to Action Letters

Guidance for Industry Classifying Resubmissions in Response to Action Letters Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document

More information

Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants

Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs

Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug

More information

Jobbetegnelser for det nuværende job i branchen

Jobbetegnelser for det nuværende job i branchen Jobbetegnelser for det nuværende job i branchen Administrerende direktør (CEO) Academic, Project manage Advanced Business Analyst Advanced Business Analyst, IT&CD, IT System Management Analytical Service

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of

More information

0 EC2 92011 V-,) 133 Lj9a

0 EC2 92011 V-,) 133 Lj9a 0 EC2 92011 V-,) 133 Lj9a Section 5: 5 1 0(k) Summar 5 10(K) SUMMARY FOR SOMATOM DEFINITION Flash (with Stellar Detector) Submitted by: Siemens Medical Solutions USA, Inc. 51 Valley Stream Parkway Malvern,

More information

OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G

OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G Vada Perkins, BSN, MSc, RN CAPT, USPHS, Chief, Business Operations Staff US Food and Drug Administration OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G "Reviewed April 2013" 2D

More information

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION TRIBAL CONSULTATION POLICY (DRAFT) Table of Contents

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION TRIBAL CONSULTATION POLICY (DRAFT) Table of Contents U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION TRIBAL CONSULTATION POLICY (DRAFT) Table of Contents 1. Background and Purpose 2. Tribal Sovereignty 3. Policy 4. Background on

More information

Food and Drug Administration FY 2011 Congressional Budget Request Table of Contents

Food and Drug Administration FY 2011 Congressional Budget Request Table of Contents Food and Drug Administration FY 2011 Congressional Budget Request Table of Contents Page Narrative by Activity FDA Program Resources Table Program Description and Accomplishments Funding History Budget

More information

The MOVIE. Currently VP, Regulatory Affairs, MCRA Former Orthopedic Devices Branch Chief (2006)

The MOVIE. Currently VP, Regulatory Affairs, MCRA Former Orthopedic Devices Branch Chief (2006) FDA played by Glenn Stiegman Currently VP, Regulatory Affairs, MCRA Former Orthopedic Devices Branch Chief (2006) Managed Orthopedic and Spine groups (Branch split in 2007) Former Orthopedic Reviewer (2000-2005)

More information

Voluntary Genomic Data Submissions at the U.S. FDA

Voluntary Genomic Data Submissions at the U.S. FDA Voluntary Genomic Data Submissions at the U.S. FDA International Conference on Harmonization Chicago, IL November 9-10, 9 2005 Felix W. Frueh, PhD Associate Director for Genomics Office of Clinical Pharmacology

More information

Lyceum of the Philippines University Batangas City CURRICULUM. Master of Science in Medical Laboratory Science

Lyceum of the Philippines University Batangas City CURRICULUM. Master of Science in Medical Laboratory Science Description: The is designed to produce scholars and high-level professionals in the field of laboratory medicine who demonstrate the professional competencies and ethical standards required in the local

More information

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Maintenance of Electronic Records

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Maintenance of Electronic Records Draft Guidance for Industry -- Not For Implementation Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Maintenance of Electronic Records Draft Guidance This guidance document

More information

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 DICOM Grid, Inc. Senior

More information

Clinical Program Director UCB BioSciences Principal Advisor reus BioPharma

Clinical Program Director UCB BioSciences Principal Advisor reus BioPharma Clinical Program Director UCB BioSciences Principal Advisor reus BioPharma J. Margaretha Oortgiesen ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY PROFESSION Strategic Planning in Regulatory

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

FY 2013 PERFORMANCE REPORT TO THE PRESIDENT AND CONGRESS. for the. Biosimilar User Fee Act

FY 2013 PERFORMANCE REPORT TO THE PRESIDENT AND CONGRESS. for the. Biosimilar User Fee Act FY 2013 PERFORMANCE REPORT TO THE PRESIDENT AND CONGRESS for the Biosimilar User Fee Act Food and Drug Administration Department of Health and Human Services FY 2013 BsUFA Performance Report Commissioner

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions

More information

BACHELOR OF SCIENCE IN MICROBIOLOGY

BACHELOR OF SCIENCE IN MICROBIOLOGY BACHELOR OF SCIENCE IN MICROBIOLOGY The goal of the B.S. Microbiology program at Albany College of Pharmacy and Health Sciences is to prepare graduates for employment or advanced study in fields requiring

More information

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

An FDA Perspective on Post- Approval Change Management for PAT and RTRT An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes

More information

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER

More information